AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY actual (%) (%)
Form 6-K / 20-F Therapy Area Product Sales Table
Latest, Q2 2026
7.0%
Period ended Jun 30, 2026
Change on a year earlier
+46.0 pts
-39.0% in Q2 2025
History
16 quarters
Since Q3 2022
Sources
16
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 7.0% | +46.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 67.0% | +134.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | -82.0% | -39.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | -57.0% | -75.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | -39.0% | -75.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | -67.0% | +20.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | -43.0% | +33.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 18.0% | +96.0 pts | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 36.0% | +126.0 pts | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | -87.0% | -21.0 pts | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | -76.0% | -51.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | -78.0% | -66.0 pts | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | -90.0% | – | Form 6-K FY2023Q2 Earnings Release ↗ |
| Q1 2023 | Mar 31, 2023 | -66.0% | – | Form 6-K FY2023Q1 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | -25.0% | – | Form 6-K FY2022Q4 Earnings Release ↗ |
| Q3 2022 | Sep 30, 2022 | -12.0% | – | Form 6-K FY2022Q3 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY actual (%) (%), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta_vi_erow_act_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.